Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

McKesson Corporation (MCK) — XLV Health Care · S&P 500 Profile |麥克森公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

McKesson Corporation (MCK) — Business, History & S&P 500 Profile |麥克森公司介紹

McKesson company profile · pharmaceutical distribution and health services · history · financial snapshot · S&P 500 rank #100 · 麥克森公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026 (Slickcharts)
Financials: FY2026 (ended Mar 31, 2026)
MARKET CAP
$123.82B
Nov 5, 2026 · Slickcharts
S&P 500 WEIGHT
0.18%
Rank #100 · Nov 5, 2026 (Slickcharts)
FY2026 TOTAL REVENUES
$403.43B
+12% YoY · North American Pharmaceutical $336.65B
FY2026 NET INCOME
$4.76B
Attributable to McKesson Corporation · Diluted EPS $38.38

SNAPSHOT

TickerMCK (NYSE)
CompanyMcKesson Corporation
GICS sector / industryHealth Care / Health Care Distributors
S&P 500 rank (by weight)#100 · 0.18% (Nov 5, 2026)
Sector rank (by S&P 500 weight)#17 in Health Care (Nov 5, 2026)
HeadquartersIrving, Texas
Founded1833, founded in New York City by Charles M. Olcott and John McKesson
CEOBrian S. Tyler (chairman & CEO)
Employees>43,000 employees, including 1,400 part-time (FY2025 10-K)
Market cap$123.82B (Nov 5, 2026)
SEC filingsEDGAR — CIK 0000927653

WHAT IT DOES

McKesson Corporation is a diversified health-care services company and the leading pharmaceutical distributor in North America. It distributes branded, generic and specialty pharmaceuticals and other health-care products, and provides related services in procurement, inventory management and logistics. Commencing in the second quarter of fiscal 2026, the company reports four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions, with its former Norwegian operations in Other. McKesson’s fiscal year ends March 31.

Fiscal 2026 revenues were $403.43B, up 12% year on year, and net income attributable to McKesson Corporation was $4.76B, or $38.38 per diluted share (adjusted EPS $39.11), against $3.30B and $25.72 in fiscal 2025. North American Pharmaceutical supplied $336.65B of revenues, Oncology & Multispecialty $48.42B, Prescription Technology Solutions $5.81B and Medical-Surgical Solutions $11.51B. Distribution is a very thin-margin business: segment operating-profit margins in fiscal 2026 were about 1.09% in North American Pharmaceutical against about 17.98% in Prescription Technology Solutions.

The growth mix is shifting toward higher-margin platforms: Oncology & Multispecialty revenues grew about 31% in fiscal 2026, helped by acquisitions and specialty distribution, while the core pharmaceutical distribution business grows with prescription volumes, including GLP-1 products.

SEGMENTS — FY2026 REVENUES

SegmentRevenuesShareYoY
North American Pharmaceutical$336.65B83.4%+10.6%
Oncology & Multispecialty$48.42B12.0%+31.4%
Prescription Technology Solutions$5.81B1.4%+11.3%
Medical-Surgical Solutions$11.51B2.9%+1.1%
Other$1.04B0.3%−4.0%
Segment revenues as disclosed for fiscal 2026 (10-K basis, new segment structure adopted in Q2 FY2026); the five rows sum to total revenues of $403.43B. Fiscal 2025 comparatives on the same structure: North American Pharmaceutical $304.51B, Oncology & Multispecialty $36.86B, Prescription Technology Solutions $5.22B, Medical-Surgical Solutions $11.38B, Other $1.09B, total $359.05B. YoY percentages computed from those comparatives.

HISTORY

YearMilestone
1833Charles M. Olcott and John McKesson found the business in New York City as a drug importer and wholesaler (Olcott & McKesson).
1967McKesson merges with Foremost Dairies to form Foremost-McKesson; the company later refocuses on health care and takes back the McKesson name.
1999McKesson merges with HBO & Company (HBOC), combining drug distribution with health-care information technology.
2019Brian S. Tyler becomes chief executive officer.

COMPETITIVE POSITION

  • The largest of the three big U.S. pharmaceutical distributors, competing with Cencora and Cardinal Health; the three together distribute the overwhelming majority of U.S. prescription drugs, so competition is on service levels, specialty handling and contract wins with retail national accounts and health systems, not on building a fourth network.
  • Scale is the economics: at $403B of revenues and a roughly 1% operating margin in the core segment, small changes in mix (specialty, oncology, GLP-1 volumes) and in working capital move earnings more than headline revenue growth.
  • The strategic pivot is toward the higher-margin platforms — oncology and multispecialty provider services and prescription-technology services — which together are still small next to distribution but carry margins an order of magnitude higher.

FINANCIAL SNAPSHOT — FY2026 (ENDED MAR 31, 2026)

Total revenues$403.43B
Net income attributable to McKesson Corporation$4.76B
Diluted EPS$38.38
Adjusted EPS (non-GAAP)$39.11
Fiscal 2026 ended Mar 31, 2026; Form 10-K filed May 8, 2026 (accession 0000927653-26-000069). Prior-year figures: total revenues $359.05B, net income attributable to McKesson Corporation $3.30B, diluted EPS $25.72, so total revenues grew 12% and net income attributable grew 45% (as reported in the fiscal 2026 results).

KEY RISKS

  • Thin-margin distribution risk: with core segment operating margins near 1%, a lost national-account contract, a pricing concession or a working-capital swing can erase a large share of segment profit.
  • Drug-pricing and policy risk: changes in U.S. drug pricing, rebate and fee structures, or in programmes such as 340B, can compress distribution economics and the value of technology services.
  • Customer and supplier concentration: revenues depend on a small number of very large retail and health-system customers and on supply terms from branded manufacturers.
  • Litigation and regulatory risk: as a national distributor, McKesson remains exposed to opioid-related and other product-distribution litigation and to state and federal investigations.

WHY IT MATTERS FOR THE S&P 500

McKesson is the S&P 500’s pharmaceutical-distribution bellwether: its prescription volumes, specialty mix and segment margins read as a gauge of U.S. medicine consumption, drug-price dynamics and health-system demand. At rank #100 by weight (0.18%) — Health Care #17 — it converts the largest revenue line in the index into a thin but highly cash-generative distribution margin.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price, market cap — Nov 5, 2026 crawl, single source)
FinancialsForm 10-K for fiscal 2026 (year ended Mar 31, 2026), filed May 8, 2026
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

McKesson

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號MCK(NYSE)
公司McKesson Corporation
GICS 板塊/行業健康護理/Health Care Distributors
標普500排名(按權重)第100名 · 0.18%(2026 年 11 月 5 日)
板塊內排名(按標普500權重)健康護理第17名(2026 年 11 月 5 日)
總部得克薩斯州歐文
成立1833年,由 Charles M. Olcott 及 John McKesson 於紐約市創立
行政總裁Brian S. Tyler(主席兼行政總裁)
員工超過43,000名員工,包括1,400名兼職(FY2025 10-K)
市值$123.82B(2026 年 11 月 5 日)
SEC 文件EDGAR — CIK 0000927653

業務概覽

麥克森公司是一家多元化健康護理服務公司,亦是北美領先的藥品分銷商。公司分銷品牌藥、仿製藥及專科藥品以及其他健康護理產品,並提供採購、庫存管理及物流等相關服務。自 fiscal 2026 第二季起,公司報告四個板塊:North American Pharmaceutical、Oncology & Multispecialty、Prescription Technology Solutions 及 Medical-Surgical Solutions,其前挪威業務列入其他。麥克森的財政年度於3月31日結束。

Fiscal 2026 收入為4,034.3億美元,同比增長12%;歸屬於麥克森公司的淨利潤為47.6億美元,攤薄每股收益38.38美元(經調整每股收益39.11美元),而 fiscal 2025 為33.0億美元及25.72美元。North American Pharmaceutical 貢獻收入3,366.5億美元,Oncology & Multispecialty 484.2億美元,Prescription Technology Solutions 58.1億美元,Medical-Surgical Solutions 115.1億美元。分銷是利潤極薄的業務:fiscal 2026 板塊營運利潤率在 North American Pharmaceutical 約為1.09%,而 Prescription Technology Solutions 約為17.98%。

增長組合正轉向利潤較高的平台:Oncology & Multispecialty 收入於 fiscal 2026 增長約31%,受惠於收購及專科分銷,而核心藥品分銷業務則隨處方量(包括 GLP-1 產品)增長。

板塊 — FY2026 收入

板塊收入佔比同比
North American Pharmaceutical3,366.5億美元83.4%+10.6%
Oncology & Multispecialty484.2億美元12.0%+31.4%
Prescription Technology Solutions58.1億美元1.4%+11.3%
Medical-Surgical Solutions115.1億美元2.9%+1.1%
其他10.4億美元0.3%−4.0%
板塊收入按 fiscal 2026 披露(10-K 基礎,FY2026 第二季起採用的新板塊架構);五行合計等於總收入4,034.3億美元。Fiscal 2025 同一架構的比較數字:North American Pharmaceutical 3,045.1億美元,Oncology & Multispecialty 368.6億美元,Prescription Technology Solutions 52.2億美元,Medical-Surgical Solutions 113.8億美元,其他10.9億美元,合計3,590.5億美元。同比百分比由該等比較數字推算。

歷史沿革

年份里程碑
1833年Charles M. Olcott 及 John McKesson 於紐約市創立該業務(Olcott & McKesson),從事藥品進口及批發。
1967年麥克森與 Foremost Dairies 合併,組成 Foremost-McKesson;公司其後重新聚焦健康護理,並恢復 McKesson 名稱。
1999年麥克森與 HBO & Company(HBOC)合併,將藥品分銷與健康護理資訊科技結合。
2019年Brian S. Tyler 出任行政總裁。

競爭地位

  • 美國三大藥品分銷商中最大的一家,與 Cencora 及 Cardinal Health 競爭;三者合計分銷美國絕大部份處方藥,故競爭在於服務水平、專科處理能力,以及與全國零售客戶及醫療系統的合約爭奪,而非建立第四個網絡。
  • 規模即經濟:以4,030億美元收入及核心板塊約1%的營運利潤率計,組合(專科、腫瘤、GLP-1 銷量)及營運資本的細微變化,對盈利的影響大於收入 headline 增長。
  • 策略轉向在於利潤較高的平台——腫瘤及多專科醫療提供者服務與處方科技服務——兩者相對分銷仍屬小型,但利潤率高出一個數量級。

財務快照 — FY2026(截至2026年3月31日)

總收入4,034.3億美元
歸屬於麥克森公司的淨利潤47.6億美元
攤薄每股收益38.38美元
經調整每股收益(非 GAAP)39.11美元
Fiscal 2026 截至2026年3月31日;10-K 於2026年5月8日提交(accession 0000927653-26-000069)。上年數字:總收入3,590.5億美元,歸屬於麥克森公司的淨利潤33.0億美元,攤薄每股收益25.72美元,故總收入增長12%,歸屬淨利潤增長45%(按 fiscal 2026 業績報告)。

主要風險

  • 薄利分銷風險:核心板塊營運利潤率接近1%,失去全國客戶合約、作出價格讓步或營運資本波動,均可抹去板塊利潤的大部份。
  • 藥價及政策風險:美國藥物定價、回扣及費用架構,或 340B 等計劃的變化,可壓縮分銷經濟效益及科技服務的價值。
  • 客戶及供應商集中風險:收入依賴少數非常大型的零售及醫療系統客戶,以及品牌藥廠的供應條款。
  • 訴訟及監管風險:作為全國分銷商,麥克森仍面臨與阿片類藥物相關及其他產品分銷的訴訟,以及州及聯邦調查。

對標普500的重要性

麥克森是標普500中藥品分銷的風向標:其處方量、專科組合及板塊利潤,可反映美國藥物消費、藥價動態及醫療系統需求。按權重排名第100位(0.18%)——健康護理第17名——它將指數中最大的收入線轉化為微薄但高度產生現金的分銷利潤。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格、市值——2026 年 11 月 5 日抓取,單一來源)
財務Fiscal 2026 10-K(截至2026年3月31日的年度),2026年5月8日提交
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

McKesson

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · MCK
Data as of Nov 5, 2026 · Financials FY2026 (10-K) · Market data Nov 2026
Previous · Automatic Data Processing, Inc. (ADP) — XLI Industrials · S&P 500 Profile |自動數據處理公司介紹Next · GE Vernova Inc. (GEV) — XLI Industrials · S&P 500 Profile |奇異維諾瓦公司介紹

Entered 2026-11-04 17:14 · updated 2026-11-14 23:47 · rev 5